Nutrition articles

Top 5 most read articles on PAHs in 2021


[ad_1]

This year’s most read articles on pulmonary arterial hypertension (PAH) covered a range of topics including nutrition, therapy changes, and patient education to improve treatment adherence. Improving patient outcomes is something they all had in common.

The topics that garnered the most attention on our Pulmonary Arterial Hypertension (PAH) compendium page this year covered investigations into the effects of nutritional risk and oxygen therapy in patients with PAH, transition between treatment regimens, the importance of patient education and the real world. data on selexipag.

Here are the 5 most read HAP articles in 2021.

5. Nutritional risk assessment can predict the prognosis of PAH at first hospitalization

In this April article, the Geriatric Nutritional Risk Index showed promise as a predictive prognostic tool in hospitalized patients with PAH or chronic thromboembolic pulmonary hypertension (HPTEC). Undernutrition has been cited as a potential trigger for disease progression in patients with precapillary pulmonary hypertension, of which PAH and HPTEC are subtypes. Additionally, since weight loss and undernutrition are common in PAH and HPTEC, the authors suggest that further studies look at nutritional interventions in people with the condition.

Read the entire article.

4. Patients with PAH can safely switch from bosentan and sildenafil to alternative therapy

With possible drug interactions in patients with PAH on bosentan and sildenafil therapy, switching from the combination of endothelin receptor antagonist / phosphodiesterase type 5 inhibitor to alternative therapy may be necessary. , according to this June article covering a retrospective study. The goal of such a decision would be to improve the effectiveness of combination therapy, the study authors noted, with future studies also investigating the effects of such a decision on clinical outcomes and hemodynamics.

Read the entire article.

3. Oxygen has potential benefits as a therapy for pulmonary arterial hypertension

Oxygen therapy may improve outcomes in patients with PAH beyond those who develop hypoxemia or low blood oxygen levels, according to this summary of study results European Journal of Preventive Cardiology March article. Several studies they reviewed highlighted potential benefits such as pulmonary hemodynamics, echocardiographic measurements, and 6-minute walking distance, while questioning the clinical effectiveness of the therapy and noting its costs. students.

Read the entire article.

2. Educational support can improve compliance with oral therapies for PAH

With tolerance and adherence considered to be the main challenges to treatment adherence, this study covered in an April article examined the results of a nursing program administered to patients taking oral therapies for the disease. HTAP. By comparing the results with patients not in the care of the program, it has been shown that education about disease status, therapy expectations and supportive tools provided through the program results in a higher number of prescriptions, drug possession rate and treatment persistence, but lower first fill rate.

Read the entire article.

1. The SPHERE registry provides a snapshot of Selexipag for treating PAH in the real world

This registry of 500 PAH patients receiving treatment with the prostacyclin agonist selexipag provides important real data on clinical characteristics, dosing regimens and clinical outcomes for people taking the drug, as discussed in this article d ‘April. Initially approved by the FDA in 2015, selexipag was found to be primarily used in patients with World Health Organization functional class II / III disease who were at intermediate risk. The United States-based Medication Observation Registry has a recruitment target of 800 patients.

Read the entire article.

[ad_2]